A subsequent post-hoc analysis, which applied a different calculation for PD-L1 positivity using the combined positivity score (CPS) instead of solely PD-L1 expression on tumor cells, identified 89% of all trial participants as PD-L1 positive, revealing a significant DFS benefit for this group (6). The gene discussed is CD274; the disease is neoplasm.